▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure tonaloxegol. Adjust
naloxegoldose and monitor side effects.oStudy
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to markedly increase the exposure tonaloxegol.
Avoid.rStudy
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure tonetupitant.o
Study
▶Netupitantis predicted to decrease the exposure to
isavuconazole.oTheoretical
▶Fluconazoleslightly to moderately increases the exposure to
nevirapine.oStudy
▶Nevirapineis predicted to decrease the exposure to
isavuconazole. Avoid.rTheoretical
▶Nevirapinemoderately decreases the exposure toitraconazole.
Avoid and for 14 days after stoppingnevirapine.oStudy
▶Nevirapinemoderately decreases the exposure to
ketoconazole. Avoid.rStudy
▶Nevirapineis predicted to decrease the exposure to
voriconazoleandvoriconazoleincreases the exposure to
nevirapine. Monitor and adjust dose.rTheoretical
▶Antifungals, azoles(fluconazole, posaconazole)are predicted to
increase the exposure tonilotinib.oTheoretical→Also
seeTABLE 9p. 849
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to moderately increase the exposure tonilotinib.
Avoid.rStudy→Also seeTABLE 9p. 849
▶Antifungals, azoles(itraconazole, ketoconazole)are predicted to
increase the exposure tonintedanib.oStudy
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure tonitisinone. Adjust dose.
oTheoretical
▶Fluconazolemoderately increases the exposure toNSAIDs
(celecoxib). Adjustcelecoxibdose.oStudy
▶Voriconazoleslightly increases the exposure toNSAIDs
(diclofenac). Monitor and adjust dose.oStudy
▶Voriconazolemoderately increases the exposure toNSAIDs
(ibuprofen). Adjust dose.oStudy
▶Fluconazoleincreases the exposure toNSAIDs(parecoxib).
Monitor and adjust dose.oStudy
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure toolaparib. Avoid
moderate inhibitors of CYP3A4 or adjustolaparibdose.
oTheoretical
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure toolaparib. Avoid potent
inhibitors of CYP3A4 or adjustolaparibdose.oStudy
▶Miconazoleis predicted to increase the exposure toopioids
(alfentanil). Use with caution and adjust dose.o
Theoretical
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure toopioids(alfentanil,
buprenorphine, fentanyl, oxycodone). Monitor and adjust dose.
oStudy
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure toopioids(alfentanil,
buprenorphine, fentanyl, oxycodone, sufentanil). Monitor and
adjust dose.rStudy
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure toopioids(methadone).
Adjust dose.rTheoretical→Also seeTABLE 9p. 849
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure toopioids(methadone,
sufentanil).oTheoretical→Also seeTABLE 9p. 849
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure tooxybutynin.n
Theoretical
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure tooxybutynin.nStudy
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure topalbociclib. Avoid or
adjustpalbociclibdose.rStudy
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure topanobinostat. Adjust
panobinostatdose; in hepatic impairment avoid.o
Study→Also seeTABLE 9p. 849
▶Posaconazoleis predicted to increase the exposure to
panobinostat. Adjust dose.oTheoretical
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure toparitaprevir(with
ritonavir and ombitasvir). Avoid.rTheoretical
▶Posaconazoleis predicted to increase the exposure to
paritaprevir(with ritonavir and ombitasvir) andparitaprevir
(with ritonavir and ombitasvir) is predicted to increase the
exposure toposaconazole. Avoid.rTheoretical
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure topazopanib.o
Theoretical→Also seeTABLE 9p. 849
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure topazopanib. Avoid or
adjustpazopanibdose.oStudy→Also seeTABLE 9p. 849
▶Miconazolegreatly increases the anticoagulant effect of
phenindione.rTheoretical
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure tophosphodiesterase
type-5 inhibitors(avanafil). Adjustavanafildose.o
Theoretical
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure tophosphodiesterase type-5
inhibitors(avanafil, vardenafil). Avoid.rStudy→Also see
TABLE 9p. 849
▶Miconazoleis predicted to increase the exposure to
phosphodiesterase type-5 inhibitors(sildenafil). Use with caution
and adjust dose.rTheoretical
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure tophosphodiesterase
type-5 inhibitors(sildenafil). Monitor or adjustsildenafildose
with moderate inhibitors of CYP3A4,p. 120.oStudy→
Also seeTABLE 9p. 849
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure tophosphodiesterase type-5
inhibitors(sildenafil). Avoid potent inhibitors of CYP3A4 or
adjustsildenafildose,p. 120.rStudy→Also seeTABLE 9
p. 849
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure tophosphodiesterase
type-5 inhibitors(tadalafil).rTheoretical
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure tophosphodiesterase type-5
inhibitors(tadalafil). Use with caution or avoid.rStudy
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure tophosphodiesterase
type-5 inhibitors(vardenafil). Adjust dose.rTheoretical→
Also seeTABLE 9p. 849
▶Antifungals, azoles(itraconazole, ketoconazole)potentially
increase the exposure topibrentasvir.oTheoretical
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure topimozide. Avoid.
rTheoretical→Also seeTABLE 9p. 849
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure topimozide. Avoid.r
Study→Also seeTABLE 9p. 849
▶Miconazoleis predicted to increase the exposure topimozide.
Avoid.oTheoretical
▶Pioglitazonepotentially decreases the exposure to
isavuconazole. Use with caution or avoid.oTheoretical
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to slightly increase the exposure toponatinib.
Monitor and adjustponatinibdose.oStudy
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to moderately increase the exposure to
praziquantel.nStudy
▶Proton pump inhibitorsdecrease the absorption of
itraconazole. Administeritraconazolecapsules with an acidic
beverage.oStudy
▶Proton pump inhibitorsdecrease the absorption of
ketoconazole. Administerketoconazolewith an acidic
beverage.oStudyBNFC 2018 – 2019 Antifungals, azoles—Antifungals, azoles 875
Interactions|Appendix 1A1